Top Message
"Building on 100 Years of Specialty Strengths to Become a Total Healthcare Company"
President, Representative Director
I am honored to have been named the new President and Representative Director. I was handed the baton by the previous president, Takashi Yamaguchi, and am now charged with guiding ASKA Pharmaceutical Holdings into the future.
The business environment surrounding the Group’s core pharmaceutical business is becoming considerably more challenging, year after year, due in part to declining birth rates, the graying of society, and annual NHI drug price revisions amid efforts to rein in social security costs. At the same time, there appears to be growing social interest in a wide range of healthcare fields, such as preventive medicine, testing, diagnostics, treatment, and prognosis. To pursue dynamic decision-making and stronger governance, we transitioned to a holding company structure in 2021 that added an animal health business and a testing business to the core pharmaceutical business. This major move was made to ensure we continue meeting the expectations of society while enhancing our corporate value, amid changes in the external environment.
Since the launch of Medium-Term Management Plan 2025 in the fiscal year ended March 31, 2022 (FY2021), the Group has set the aim of becoming a total healthcare company with a strong foundation in specialty pharmaceuticals. FY2025 marks the final year of the plan. I recognize that, as the president, I have been entrusted with the major mission of getting us across the finish line by achieving our Groupwide numerical targets of ¥70.0 billion in net sales, an operating profit margin of 8%, and an ROE of 8%. Furthermore, as part of the plan’s final year mission, I seek to further strengthen our business foundation in Japan and uncover new opportunities for growth in overseas markets.
To advance the next phase of the overseas business, the Group made the Vietnam-based pharmaceutical company Ha Tay Pharmaceutical Joint Stock Company (“Hataphar”) a consolidated subsidiary in February 2025. With this expansion, we aim to further bolster the entire Group’s growth and corporate value.
The origins of the Company can be traced back to 1920 when Yasohachi Yamaguchi, our founder, established Teikoku Hormone Research Institute and began the research, manufacture, and sale of hormone formulations based on the unique idea of creating drugs from animal organs. In the more than 100 years since then, we have continued to refine our drug discovery capabilities. Going forward, we will continue to take on new challenges and redouble our efforts under our corporate philosophy: “Contribute toward the improvement of people’s health and progress in society through the development of innovative products.”
We appreciate the continued understanding and support of our stakeholders.
Sohta Yamaguchi
President, Representative Director
(As of June 24, 2025)